Trial Profile
Hematopoietic toxicity study of Zevalin [ibritumomab tiuxetan Y-90] treated patients with non-Hodgkin's lymphoma
Status:
Not stated
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 19 Feb 2007
Price :
$35
*
At a glance
- Drugs Ibritumomab tiuxetan (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 19 Feb 2007 New trial record.